|
A phase III randomized controlled trial comparing palliative stereotactic body radiotherapy vs. palliative standard radiotherapy in patients with advanced head and neck cancer (NCT06641791). |
| |
|
No Relationships to Disclose |
| |
|
|
Consulting or Advisory Role - EMD Serono/Merck |
Travel, Accommodations, Expenses - Elekta |
| |
|
|
Consulting or Advisory Role - AstraZeneca; EMD Serono; Need; Sanofi |
Research Funding - AstraZeneca; Varian Medical Systems |
| |
|
No Relationships to Disclose |
| |
|
Stock and Other Ownership Interests - Need |
|
Consulting or Advisory Role - Need |
| |
|
No Relationships to Disclose |
| |
|
Employment - Princess Margaret Cancer Centre |
Honoraria - Varian Medical Systems; Varian Medical Systems; Varian Medical Systems |
Consulting or Advisory Role - Varian Medical Systems |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
|
|
Stock and Other Ownership Interests - Adela |
Consulting or Advisory Role - EMD Serono |
Patents, Royalties, Other Intellectual Property - Co-inventor and holder of a patent related to circulating tumor DNA detection technology.; Co-inventor of patent application pending related to detection of HPV circulating cell-free DNA. (Inst); Co-inventor of patents related to cell-free DNA methylation analysis technology. (Inst) |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Stock and Other Ownership Interests - Varian, a Siemens Healthineers Company (I) |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |